cd20
-
Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study, 2026, D’Orso et al.
Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study Abstract CD20-targeting monoclonal antibodies are highly effective therapies for relapsing multiple sclerosis (MS). We examined how anti-CD20 therapy reshapes antiviral T-cell...- Chandelier
- Thread
- cd20 multiple sclerosis
- Replies: 0
- Forum: Other health news and research
-
Characterizing post-COVID-19 syndrome in multiple sclerosis: Vaccine status, infection burden, and therapy categories as predictors, 2025, Sharma +
Characterizing post-COVID-19 syndrome in multiple sclerosis: Vaccine status, infection burden, and therapy categories as predictors Deepak Sharma ∙ Christian P. Kamm ∙ Robert Hoepner ∙ Iris-Katharina Penner ∙ Thomas Nyffeler ∙ Lara Diem [Line breaks added] Background Post-COVID-19 syndrome...- forestglip
- Thread
- cd20 long covid monoclonal antibody multiple sclerosis rituximab s1pr sphingosine-1-phosphate
- Replies: 1
- Forum: Long Covid research
-
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study,2023,Venkat+
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study Venkat, Rathnam K; Wang, Xiaosong; Patel, Naomi J; Kawano, Yumeko; Schiff, Abigail; Kowalski, Emily N; Cook, Claire E; Vanni, Kathleen M M; Qian, Grace; Bade...- SNT Gatchaman
- Thread
- cd20 long covid rheumatology risk factors rituximab
- Replies: 3
- Forum: Long Covid research